alpelisib
novartis
['bcsm', 'alpelisib', 'solar-1', 'biomarker']
solar-1 biomarker analysis, alpelisib+fulvestrant. 80% were primary tumor samples, 20% were metastatic. more alpelisib benefit in low tmb. no impact of fgfr alteration. myc amplification confers resistance.
dejan juric of #asco22 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.